In Italy and all of Europe, at the time of this study, the ICIs pembrolizumab and atezolizumab, or chemotherapy alone, based on histology, were approved for patients with advanced NSCLC and PDL1 > 50%. This evidence concerns the gene CD274 and non-small cell lung carcinoma.